Whitebox Advisors’s Aspire Biopharma ASBP Stock Holding History

Whitebox Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-208	Closed	-$2.63M	–	464
2023 Q1	$2.63M	Hold	208	–	–	0.09%	108
2022 Q4	$2.58M	Hold	208	–	–	0.07%	138
2022 Q3	$2.54M	Hold	208	–	–	0.07%	139
2022 Q2	$2.5M	Buy	+208	New	+$2.49M	0.08%	138

Other funds holding ASBP

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Whitebox Advisors's ASBP Position: Q2 2023 in Review

Whitebox Advisors sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 208 shares — an estimated $2.63M sold.

Whitebox Advisors first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $2.63M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

Whitebox Advisors reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
Whitebox Advisors sold 208 Aspire Biopharma shares in Q2 2023, an estimated $2.63M.
Whitebox Advisors first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
Whitebox Advisors's Aspire Biopharma position peaked at $2.63M in Q1 2023.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Whitebox Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.